Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone

Cancer Science

Volumn 105, Issue 6, 2014, Pages 744-748

  Kato Kaneko, Mika ^a   Liu, Xing ^a,b   Oki, Hiroharu ^a,b   Ogasawara, Satoshi ^a   Nakamura, Takuro ^a   Saidoh, Noriko ^a   Tsujimoto, Yuta ^a   Matsuyama, Yuka ^a   Uruno, Akira ^a   Sugawara, Masato ^b   Tsuchiya, Takashi ^b   Yamakawa, Mitsunori ^b   Yamamoto, Masayuki ^a   Takagi, Michiaki ^b   Kato, Yukinari ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

GCTB; Giant cell tumor of bone; IDH mutations; Isocitrate dehydrogenase 2; Monoclonal antibody

Indexed keywords

ISOCITRATE DEHYDROGENASE;

ADULT; ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR CLONING; MUTATIONAL ANALYSIS; OSTEOCLASTOMA; PRIORITY JOURNAL;

GCTB; GIANT CELL TUMOR OF BONE; IDH MUTATIONS; ISOCITRATE DEHYDROGENASE 2; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BONE NEOPLASMS; FEMALE; GIANT CELL TUMOR OF BONE; GLUTARATES; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; KETOGLUTARIC ACIDS; MALE; MIDDLE AGED; MUTATION; OSTEOSARCOMA; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84901772969     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12413     Document Type: Article

References (23)

1. Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am 2006; 37: 35-51.
2. Szendroi M. Giant-cell tumour of bone. J Bone Joint Surg Br 2004; 86: 5-12.
3. Balke M, Hardes J. Denosumab: a breakthrough in treatment of giant-cell tumour of bone? Lancet Oncol 2010; 11: 218-9.
4. Schwartz HS, Eskew JD, Butler MG. Clonality studies in giant cell tumor of bone. J Orthop Res 2002; 20: 387-90.
5. Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone 2013; 52: 238-46.
6. Atkins GJ, Kostakis P, Vincent C et al. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006; 21: 1339-49.
7. Behjati S, Tarpey PS, Presneau N et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013; 45: 1479-82.
8. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44.
9. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.
10. Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-34.
11. Pansuriya TC, van Eijk R, d'Adamo P et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43: 1256-61.
12. Liu X, Kato Y, Kaneko MK et al. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med 2013; 2: 803-14.
13. Moriya K, Kaneko MK, Liu X et al. IDH2 and TP53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome. Cancer Sci 2014; 105: 359-62.
14. Kaneko M, Ogasawara S, Kato Y. Establishment of a novel multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. Tohoku J Exp Med 2013; 230: 103-9.
15. Ogasawara S, Kaneko MK, Tsujimoto Y, Liu X, Kato Y. A multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations. Monoclon Antib Immunodiagn Immunother 2013; 32: 377-81.
16. Fujii Y, Kaneko M, Neyazaki M, Nogi T, Kato Y, Takagi J. PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin. Protein Expr Purif 2014; 95: 240-7.
17. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009; 390: 547-51.
18. Kaneko MK, Tian W, Takano S, et al. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun 2011; 406: 608-13.
19. Kaneko MK, Tsujimoto Y, Hozumi Y, Goto K, Kato Y. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations. Monoclon Antib Immunodiagn Immunother 2013; 32: 224-8.
20. Kaneko MK, Morita S, Tsujimoto Y, et al. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochem Biophys Res Commun 2013; 432: 40-5.
21. Kato Y, Kaneko MK. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation. Biochem Biophys Res Commun 2013; 433: 374-8.
22. Kato Y, Natsume A, Kaneko MK. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochem Biophys Res Commun 2013; 432: 564-7.
23. Takano S, Kato Y, Yamamoto T, et al. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neuro oncol 2012; 108: 361-73.